Table 3 Correlation between CBP and GCN5 expression and the status of ER, PR, HER2 and ki-67 in tissue samples from breast cancer patients
From: The impact of CBP expression in estrogen receptor-positive breast cancer
Molecular subtypes | Total | No. of missing data (%) | CBP expression | Total | No. of missing data (%) | GCN5 expression | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Negative (%)a | Positive (%)b | p valuec | Negative (%)a | Positive (%)b | p valuec | |||||
ER status | ||||||||||
Negative | 75 | Ā | 17 (22.7) | 58 (77.3) | 0.0001 | 78 | Ā | 14 (17.9) | 64 (82.1) | 0.213 |
Positive | 124 | Ā | 6 (4.8) | 118 (95.2) | Ā | 123 | Ā | 14 (11.4) | 109 (88.6) | Ā |
Total | 199 | 10 (4.8) | Ā | Ā | Ā | 201 | 10 (4.7) | Ā | Ā | Ā |
PR status | ||||||||||
Negative | 71 | Ā | 17 (23.9) | 54 (76.1) | 0.0001 | 74 | Ā | 13 (17.6) | 61 (82.4) | 0.541 |
Positive | 125 | Ā | 7 (5.6) | 118 (94.4) | Ā | 123 | Ā | 17 (13.8) | 106 (86.2) | Ā |
Total | 196 | 13 (6.2) | Ā | Ā | Ā | 197 | 14 (6.6) | Ā | Ā | Ā |
HER2 | ||||||||||
Negative | 180 | Ā | 22 (12.2) | 158 (87.8) | 1.000 | 181 | Ā | 26 (14.4) | 155 (85.6) | 0.552 |
Positive (>ā30%) | 21 | Ā | 3 (14.3) | 18 (85.7) | Ā | 22 | Ā | 2 (9.1) | 20 (90.9) | Ā |
Total | 201 | 8 (3.8) | Ā | Ā | Ā | 203 | 8 (3.8) | Ā | Ā | Ā |
Ki-67 status | ||||||||||
ā¤ā20% | 183 | Ā | 22 (12.0) | 161 (88.0) | 0.354 | 184 | Ā | 30 (16.3) | 154 (83.7) | 0.094 |
>ā20% | 24 | Ā | 4 (16.7) | 20 (83.3) | Ā | 24 | Ā | 1 (4.2) | 23 (95.8) | Ā |
Total | 207 | 2 (1.0) | Ā | Ā | Ā | 208 | 3 (1.4) | Ā | Ā | Ā |